M&A Deal Summary

Amphastar Pharmaceuticals Acquires International Medication Systems

On August 4, 2016, Amphastar Pharmaceuticals acquired life science company International Medication Systems from UCB for 8M USD

Acquisition Highlights
  • This is Amphastar Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Amphastar Pharmaceuticals’ largest (disclosed) transaction.
  • This is Amphastar Pharmaceuticals’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2016-08-04
Target International Medication Systems
Sector Life Science
Buyer(s) Amphastar Pharmaceuticals
Sellers(s) UCB
Deal Type Divestiture
Deal Value 8M USD

Target

International Medication Systems

Berkshire, United Kingdom
International Medication Systems (UK) Ltd. is pharmaceutical company provides generic and proprietary injectable, inhalation, and intranasal products.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amphastar Pharmaceuticals

Rancho Cucamonga, California, United States
Category Company
Founded 1996
Sector Life Science
Employees1,761
Revenue 644M USD (2023)
DESCRIPTION

Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Amphastar Pharmaceuticals was incorporated in 1996 and is based in Rancho Cucamonga, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United Kingdom) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

UCB

Brussels, Belgium
Category Company
Founded 1928
Sector Healthcare Services
Employees9,000
Revenue 5.3B EUR (2023)
DESCRIPTION

UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.

DEAL STATS #
Overall 6 of 7
Sector (Life Science) 5 of 6
Type (Divestiture) 5 of 6
Country (United Kingdom) 1 of 1
Year (2016) 2 of 2
Size (of disclosed) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-01 UCB - Three Cardiovascular Products

Belgium

UCB - Three Cardiovascular Products consists of Elantan®, Isoket® and Deponit® rights is a producer of medical products to treat both acute and chronic coronary artery disease.

Sell €92M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-06-06 Beryllium Discovery

Bedford, Massachusetts, United States

Beryllium Discovery LLC is a drug discovery contract research organization (CRO), provides research services and engages in collaborations with pharmaceutical, innovative biotechnology, and academic partners based on its innovative drug discovery platform. Beryllium Discovery LLC was founded in 1999 and is based in Bedford, Massachusetts.

Buy -
Mergr

Product

Company

Legal